{"id":"nct:NCT06267560","kind":"trial","title":"Lp(a) Lowering Study of Pelacarsen (TQJ230) in US Black/African American and Hispanic Participants With Elevated Lp(a) and Established ASCVD","authors":["Novartis Pharmaceuticals"],"author_count":1,"year":2024,"published":"2024-02-20","venue":"ClinicalTrials.gov","cited_by":null,"doi":null,"arxiv_id":null,"nct_id":"NCT06267560","source_url":"https://clinicaltrials.gov/study/NCT06267560","archive_url":"https://space-kitty.com/papers/nct:NCT06267560","updated":"2026-08-10","pmid":null,"pmcid":null,"openalex_id":null,"pdf_url":null,"abstract":"Study CTQJ230A12303 is a randomized, double-blind placebo-controlled, Phase IIIb study to evaluate the efficacy, safety and tolerability of pelacarsen (TQJ230) 80 mg s.c. QM compared with placebo s.c. QM in US Black/African American and Hispanic participants with established ASCVD and elevated levels of Lp(a) who are treated for cardiovascular (CV) risk factors according to local practice/guidelines for the reduction of cardiovascular risk.","abstract_license":"ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters","license":"ClinicalTrials.gov terms (attribution, processing date, modifications noted)","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":["Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease"],"details":{"acronym":null,"status":"COMPLETED","phase":"PHASE3","study_type":"INTERVENTIONAL","enrollment":422,"sponsor":"Novartis Pharmaceuticals","conditions":["Elevated Lp(a) and Established Atherosclerotic Cardiovascular Disease"],"interventions":["DRUG: TQJ230","DRUG: Placebo"],"start_date":"2024-04-24","start_date_type":"ACTUAL","primary_completion_date":"2026-03-25","has_results":false,"data_source":"ClinicalTrials.gov","data_processed":"2026-10-29T09:00:05","modifications":"selected fields only; whitespace normalized; brief summary truncated to 2,000 characters"},"provenance":"clinicaltrials","attribution":"Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.","topics":[{"slug":"cardiovascular-innovation","name":"Cardiovascular Therapeutics","domain_slug":"medicine"}],"cited_in_dossiers":[]}